Kazia Therapeutics Ltd ADR

Kazia Therapeutics Limited is an oncology-focused biotechnology company. Its lead candidate, paxalisib, is a small-molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway being studied in Phase II/III trials for glioblastoma, in Phase II trials for isocitrate dehydrogenase-mutant glioma, primary CNS lymphoma, diffuse intrinsic pontine glioma, and brain metastases, and in preclinical studies for triple-negative breast cancer and atypical rhabdoid/teratoid tumors. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 in Phase I trials for advanced solid tumors and ovarian cancer. It has collaborations with several organizations, was formerly known as Novogen Limited, changed its name in November 2017, was incorporated in 1994, and is based in Sydney, Australia.